Early clinical studies of BTK inhibitors focused heavily on RA as their first clinical indication with 9 of the 13 BTK inhibitors having been tested, yet only 1 (fenebrutinib) reported positive data [(74); Table 1]. This evidence concerns the gene BTK and rheumatoid arthritis.